SCHEMBL6351364

SCHEMBL6351364

O=C(CCN1CCN(c2ncccn2)CC1)c1ccc(Cl)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 6/20 0.78
DRD4 P21917 2/20 0.66
DRD2 P14416 1/20 0.66
ADRA2C P18825 1/20 0.66
HTR2A P28223 1/20 0.66
HTR2C P28335 1/20 0.66
HRH1 P35367 1/20 0.66
DRD3 P35462 1/20 0.66
KMT2A Q03164 3/20 0.63
ALDH1A1 P00352 2/20 0.63
MAPT P10636 1/20 0.63
TMEM97 Q5BJF2 1/20 0.61
SIGMAR1 Q99720 1/20 0.61
MEN1 O00255 1/20 0.58
SOD1 P00441 1/20 0.58
KDM4E B2RXH2 1/20 0.57
TSHR P16473 1/20 0.57
HTT P42858 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
SLC6A7 Q99884 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6360134 0.88 HTR1A (1.00) HTR1ADRD4DRD2ADRA2CHTR2A
SCHEMBL6351426 0.86 HTR1A (0.81) HTR1ADRD4DRD2HTR2AHTR2C
SCHEMBL6353487 0.79 DRD4 (0.78) DRD4DRD2
SCHEMBL6358057 0.79 DRD4 (0.78) DRD4DRD2
SCHEMBL6353483 0.79 DRD4 (0.78) DRD4DRD2
SCHEMBL9633626 0.79 HTR1A (0.77) HTR1ADRD4DRD2ADRA2CHTR2A
SCHEMBL5954175 0.79 KMT2A (0.70) HTR1ADRD4DRD2HTR2AHTR2C
SCHEMBL10422213 0.79 HTR1A (0.69) HTR1ADRD4DRD2ADRA2CHTR2A
SCHEMBL22651537 0.78 ALDH1A1 (0.70) HTR1ADRD4DRD2ADRA2CHTR2A
SCHEMBL29773062 0.78 ALDH1A1 (0.70) HTR1ADRD4DRD2ADRA2CHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050176727-A1 Oximes and hydrazones that are useful in treating sexual dysfunction ABBOTT LABORATORIES 2005-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176727-A1 Oximes and hydrazones that are useful in treating sexual dysfunction CYP19A1, SHBG, CYP17A1 HTR1A 871/4885DRD4 1272/4885DRD2 1704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.